Presentations from the Virtual Perspectives in Urology:
Point-Counterpoint 2020, November 11-12, 2020

PROSTATE CANCER

Moderator: E. David Crawford, MD

Point-Counterpoint 1: All Men with Prostate Cancer (Active Surveillance, High-Risk Local) and All Patients with Advanced Disease Should Undergo Germline Testing (BRCA 1 and 2)

All Men with Prostate Cancer and All Patients with Advanced Disease Should Undergo Germline Testing

Brian T. Helfand, MD, PhD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

Universal Germline Screening in Prostate Cancer: The Argument Against

Alan H. Bryce, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

Point-Counterpoint 2: Men with High-Risk Prostate Cancer Should Undergo
Neoadjuvant Therapy Prior to Surgery

Neoadjuvant Trials in High Risk Prostate Cancer: A Must Do for the Field!

Robert E. Reiter, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

Men with High-risk Prostate Cancer Should NOT Undergo Neoadjuvant Therapy Prior to Surgery

J. Kellogg Parsons, MD, MHS, FACS, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

In My Opinion: Tele-Urology – Is This a Policy Imperative?

Neil H. Baum, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

In My Opinion: Biomarkers for the Diagnosis of Prostate Cancer

Michael A. Gorin, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

Point-Counterpoint 3: nmCRPC Next Generation Imaging versus Standard Imaging –
Finding Advanced Disease Earlier Matters

Non-Metastatic CRPC: Finding Advanced Disease with Next Generation Imaging Matters

Gerald L. Andriole, Jr., MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

The Case for Standard Imaging

Michael L. Glode, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

In My Opinion: The Future of Independent Practice

Edward S. Cohen, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

Prostate Cancer Imaging: Are We Done, or Is There More?

Robert E. Reiter, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 11, 2020.

UROTHELIAL CANCERS

Moderator: Dan Theodorescu, MD, PhD

Point-Counterpoint 1: Management of BCG-Unresponsive Cystectomy-Ineligible Bladder Cancer Patients Pembrolizumab (Intravenous)

Management of BCG-Unresponsive Cystectomy-Ineligible Bladder Cancer Patients: Pembrolizumab

Daniel P. Petrylak, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 12, 2020.

Nadofaragene Firadenovec for BCG Unresponsive NMIBC

Colin P. N. Dinney, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 12, 2020.

Point-Counterpoint 2: Neoadjuvant Immune-Checkpoint Inhibition vs. Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer (MIBC)

Neoadjuvant Immune-Checkpoint Inhibition vs. Neoadjuvant Cisplatin-Based Chemotherapy

Petros Grivas, MD, PhD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 12, 2020.

Neoadjuvant Immune-Checkpoint Inhibition vs. Neoadjuvant Cisplatin-Based Chemotherapy for MIBC Con

Robert R. Dreicer, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 12, 2020.

Point-Counterpoint 3: Neoadjuvant vs. Adjuvant Chemotherapy in Upper Tract Urothelial Cancer

Neoadjuvant Therapy for Upper Tract Urothelial Carcinoma

Seth P. Lerner, MD, presented this lecture during the Perspectives in Urology Point • Counterpoint on November 12, 2020.

Point-Counterpoint: Neoadjuvant vs. Adjuvant Chemotherapy in UTUC